scholarly journals Pyruvate dehydrogenase activity in hamster small intestine during development

1977 ◽  
Vol 164 (3) ◽  
pp. 693-697 ◽  
Author(s):  
C M Schiller
Keyword(s):  
Pyruvate Dehydrogenase ◽  
Redox State ◽  
Direct Relationship ◽  
Active Form ◽  
Total Activity ◽  
Complete Conversion ◽  
Mitochondrial Redox State ◽  
Nadh Ratio

Total pyruvate dehydrogenase activities in hamster intestine increase from 40 nmol/min (munits) per g of intestine in the foetal animals to 460 munits/g in the adult, whereas the fraction of the enzyme in the active form increases from 34 to 42% of the total activity over the same period. However, a complete conversion of the enzyme into the active form is observed in the neonatal animal immediately after birth. Results from experiments in vitro suggested that the activation of pyruvate dehydrogenase is controlled, in part, by the [NAD+]/[NADH] ratio. This proposal was tested in vivo by examining the proportion of the enzyme in the active form during conditions when the [NAD+]/[NADH] ratio was markedly altered, and the data show a direct relationship between the mitochondrial redox state and activity of the active form.

scholarly journals hSirT1-Dependent Regulation of the PCAF-E2F1-p73 Apoptotic Pathway in Response to DNA Damage

2009 ◽  
Vol 29 (8) ◽  
pp. 1989-1998 ◽  
Author(s):  
Natalia Pediconi ◽  
Francesca Guerrieri ◽  
Stefania Vossio ◽  
Tiziana Bruno ◽  
Laura Belloni ◽  
...  
Keyword(s):  
Dna Damage ◽  
Cell Survival ◽  
Stress Responses ◽  
Promoter Activity ◽  
Redox State ◽  
Apoptotic Pathway ◽  
Nadh Ratio ◽  
P53 Status

ABSTRACT The NAD+-dependent histone deacetylase hSirT1 regulates cell survival and stress responses by inhibiting p53-, NF-κB-, and E2F1-dependent transcription. Here we show that the hSirT1/PCAF interaction controls the E2F1/p73 apoptotic pathway. hSirT1 represses E2F1-dependent P1p73 promoter activity in untreated cells and inhibits its activation in response to DNA damage. hSirT1, PCAF, and E2F1 are corecruited in vivo on theP1p73 promoter. hSirT1 deacetylates PCAF in vitro and modulates PCAF acetylation in vivo. In cells exposed to apoptotic DNA damage, nuclear NAD+ levels decrease and inactivate hSirT1 without altering the hSirT1 interaction with PCAF and hSirT1 binding to the P1p73 promoter. The reactivation of hSirT1 by pyruvate that increases the [NAD+]/[NADH] ratio completely abolished the DNA damage-induced activation of TAp73 expression, thus linking the modulation of chromatin-bound hSirT1 deacetylase activity by the intracellular redox state with P1p73 promoter activity. The release of PCAF from hSirT1 repression favors the assembly of transcriptionally active PCAF/E2F1 complexes onto the P1p73 promoter and p53-independent apoptosis. Our results identify hSirT1 and PCAF as potential targets to modulate tumor cell survival and chemoresistance irrespective of p53 status.

scholarly journals Targeting glutamine metabolism and redox state for leukemia therapy

2018 ◽  
Author(s):  
Mark A. Gregory ◽  
Travis Nemkov ◽  
Vadym Zaberezhnyy ◽  
Hae J. Park ◽  
Sarah Gehrke ◽  
...  
Keyword(s):  
Cell Death ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Redox State ◽  
Glutamine Metabolism ◽  
Leukemia Cells ◽  
Mitochondrial Redox State ◽  
Acute Myeloid

AbstractAcute myeloid leukemia (AML) is a hematological malignancy characterized by the accumulation of immature myeloid precursor cells. AML is poorly responsive to conventional genotoxic chemotherapy and a diagnosis of AML is usually fatal. More effective and less toxic forms of therapy are desperately needed. AML cells are known to be highly dependent on the amino acid glutamine for their survival. Here, we show that blocking glutamine metabolism through the use of a glutaminase inhibitor (CB-839) significantly impairs antioxidant glutathione production in multiple types of AML, resulting in accretion of mitochondrial reactive oxygen species (mitoROS) and apoptotic cell death. Moreover, glutaminase inhibition makes AML cells susceptible to adjuvant drugs that further perturb mitochondrial redox state, such as arsenic trioxide (ATO) and homoharringtonine (HHT). Indeed, the combination of ATO or HHT with CB-839 exacerbates mitoROS and apoptosis, and leads to more complete cell death in AML cell lines, primary AML patient samples andin vivousing mouse models of AML. In addition, these redox-targeted combination therapies are effective in eradicating acute lymphoblastic leukemia cellsin vitroandin vivo. Thus, targeting glutamine metabolism in combination with drugs that perturb mitochondrial redox state represents an effective and potentially widely applicable therapeutic strategy for treating multiple types of leukemia.Key PointsGlutaminase inhibition commonly impairs glutathione metabolism and induces mitochondrial oxidative stress in acute myeloid leukemia cellsA glutaminase inhibitor synergizes with pro-oxidant drugs in inducing apoptosis and eliminating leukemia cellsin vitroandin vivo

Pyruvate dehydrogenase activity in liver and brown fat of the developing rat

1976 ◽  
Vol 54 (6) ◽  
pp. 534-538 ◽  
Author(s):  
Kathryn Bailey ◽  
Peter Hahn ◽  
Vladimir Palaty
Keyword(s):  
Pyruvate Dehydrogenase ◽  
Neonatal Period ◽  
Fetal Liver ◽  
Active Form ◽  
Total Activity ◽  
Brown Fat ◽  
Suckling Period ◽  
Brown Adipose ◽  
Developing Rat

The total activity of pyruvate dehydrogenase (EC 1.2.4.1) and the fraction of the enzyme in the active form were assayed in brown fat and liver throughout the development of the rat.In brown adipose tissue, the total activity increased until the late suckling period. After weaning, a decrease was noted. The fraction of the enzyme in the active form did not increase until after 10 days of age, reached its highest level in the late suckling period and remained at this level after weaning.Pyruvate dehydrogenase in liver decreased in both total activity and percentage activity in the early neonatal period. Both parameters increased after this period, reaching their highest levels in the late suckling period.In both fetal liver and fetal brown fat, the total activity of pyruvate dehydrogenase was increased by in vitro incubation with insulin.

scholarly journals Development of 18F-Labeled Radiotracers for PET Imaging of the Adenosine A2A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation

2021 ◽  
Vol 22 (5) ◽  
pp. 2285
Author(s):  
Thu Hang Lai ◽  
Susann Schröder ◽  
Magali Toussaint ◽  
Sladjana Dukić-Stefanović ◽  
Mathias Kranz ◽  
...  
Keyword(s):  
Specific Binding ◽  
Brain Slices ◽  
Total Activity ◽  
Biological Evaluation ◽  
Adenosine A2a Receptor ◽  
Positron Emission ◽  
A2a Receptor ◽  
Adenosine A2a

The adenosine A2A receptor (A2AR) represents a potential therapeutic target for neurodegenerative diseases. Aiming at the development of a positron emission tomography (PET) radiotracer to monitor changes of receptor density and/or occupancy during the A2AR-tailored therapy, we designed a library of fluorinated analogs based on a recently published lead compound (PPY). Among those, the highly affine 4-fluorobenzyl derivate (PPY1; Ki(hA2AR) = 5.3 nM) and the 2-fluorobenzyl derivate (PPY2; Ki(hA2AR) = 2.1 nM) were chosen for 18F-labeling via an alcohol-enhanced copper-mediated procedure starting from the corresponding boronic acid pinacol ester precursors. Investigations of the metabolic stability of [18F]PPY1 and [18F]PPY2 in CD-1 mice by radio-HPLC analysis revealed parent fractions of more than 76% of total activity in the brain. Specific binding of [18F]PPY2 on mice brain slices was demonstrated by in vitro autoradiography. In vivo PET/magnetic resonance imaging (MRI) studies in CD-1 mice revealed a reasonable high initial brain uptake for both radiotracers, followed by a fast clearance.

scholarly journals Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism

2009 ◽  
Vol 296 (1) ◽  
pp. C65-C74 ◽  
Author(s):  
Xin Zheng ◽  
Fei Chu ◽  
Pauline M. Chou ◽  
Christine Gallati ◽  
Usawadee Dier ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Cell ◽  
Trichostatin A ◽  
Cathepsin L ◽  
Active Form ◽  
Cancer Resistance ◽  
Protease Inhibition ◽  
Resistance To Chemotherapy

Cathepsin L is a lysosomal enzyme thought to play a key role in malignant transformation. Recent work from our laboratory has demonstrated that this enzyme may also regulate cancer cell resistance to chemotherapy. The present study was undertaken to define the relevance of targeting cathepsin L in the suppression of drug resistance in vitro and in vivo and also to understand the mechanism(s) of its action. In vitro experiments indicated that cancer cell adaptation to increased amounts of doxorubicin over time was prevented in the presence of a cathepsin L inhibitor, suggesting that inhibition of this enzyme not only reverses but also prevents the development of drug resistance. The combination of the cathepsin L inhibitor with doxorubicin also strongly suppressed the proliferation of drug-resistant tumors in nude mice. An investigation of the underlying mechanism(s) led to the finding that the active form of this enzyme shuttles between the cytoplasm and nucleus. As a result, its inhibition stabilizes and enhances the availability of cytoplasmic and nuclear protein drug targets including estrogen receptor-α, Bcr-Abl, topoisomerase-IIα, histone deacetylase 1, and the androgen receptor. In support of this, the cellular response to doxorubicin, tamoxifen, imatinib, trichostatin A, and flutamide increased in the presence of the cathepsin L inhibitor. Together, these findings provided evidence for the potential role of cathepsin L as a target to suppress cancer resistance to chemotherapy and uncovered a novel mechanism by which protease inhibition-mediated drug target stabilization may enhance cellular visibility and, thus, susceptibility to anticancer agents.

Metabolic influences on enzymes of glycogen synthesis and breakdown in adipose tissue

1964 ◽  
Vol 207 (6) ◽  
pp. 1215-1220 ◽  
Author(s):  
Alisa Gutman ◽  
Eleazar Shafrir
Keyword(s):  
Adipose Tissue ◽  
Protein Content ◽  
Glycogen Synthesis ◽  
Total Activity ◽  
Epididymal Adipose Tissue ◽  
Control Value ◽  
Prolonged Fast ◽  
Rat Adipose Tissue

Rat adipose tissue from different body sites was shown to contain uridine diphosphoglucose (UDPG)-transglucosylase activity, which on the basis of protein content was comparable to or higher than that reported for muscle or liver. In epididymal adipose tissue, the activity of UDPG-glycogen transglucosylase and phosphorylase, as well as the content of glycogen per wet weight, decreased with increasing age of the animals in parallel with the decrease of tissue protein content. On prolonged fast the activity of UDPG-glycogen transglucosylase and phosphorylase per milligram protein dropped by 25–50% of the control value. On refeeding, the extent of changes was variable but, in general, at 24 hr control or higher levels of activity were reached and at 48 hr the activities were elevated. The ratio of glucose 6-phosphate independent activity of UDPG-glycogen transglucosylase to total activity was not affected by fasting and refeeding or by the administration of glucose with insulin. In adrenalectomized rats, with high adipose tissue glycogen, no change in UDPG-glycogen transglucosylase was found, whereas the levels of phosphorylase were elevated. Epinephrine in vivo and in vitro did not affect the activity of UDPG-glycogen transglucosylase of adipose tissue.

Intercellular Invertase in Developing Peach Mesocarp

1988 ◽  
Vol 15 (3) ◽  
pp. 377 ◽  
Author(s):  
TD Ugalde ◽  
DJ Chalmers ◽  
PH Jerie
Keyword(s):  
Dry Matter ◽  
Prunus Persica ◽  
Total Activity ◽  
Insoluble Fraction ◽  
Acid Invertase ◽  
Dry Matter Accumulation ◽  
Tissue Slices ◽  
Insoluble Particles

Acid invertase (β-fructofuranosidase, EC 3.2.1.26) was extracted from peach mesocarp (Prunus persica (L.) Batsch) using a range of extraction conditions. The enzyme always was attached to insoluble particles in the crude homogenate and was bound by a mechanism that could not have arisen during extraction. The activity in the insoluble fraction made up (essentially) all of the total activity extracted from the tissue and was the same as the activity shown by whole tissue slices placed directly into the assay solution. These results demonstrate that most of the acid invertase in developing peach mesocarp is located outside the cell. The amount of this enzyme, as measured in vitro, did not change during development at times when the rate of dry matter increase was changing rapidly. Either the action of intercellular invertase is not associated with the control of dry matter accumulation in peach mesocarp, or control is effected through activity of the enzyme in vivo, not its synthesis or degradation.

In vitro secretion of atrial natriuretic factor: receptor-mediated release of prohormone

1988 ◽  
Vol 254 (5) ◽  
pp. R809-R814 ◽  
Author(s):  
A. T. Veress ◽  
S. Milojevic ◽  
C. Yip ◽  
T. G. Flynn ◽  
H. Sonnenberg
Keyword(s):  
Atrial Natriuretic Factor ◽  
Active Form ◽  
High Concentration ◽  
Natriuretic Factor ◽  
Rat Hearts ◽  
Agonist Concentration ◽  
Atrial Natriuretic Factor Receptor ◽  
Atrial Natriuretic

Secretion of atrial natriuretic factor (ANF) in vivo is thought to be mediated by atrial distension. We have shown previously that nonstretched atria can release natriuretic activity in vitro when stimulated by certain agonists. In the present study atrial appendages from freshly excised rat hearts were incubated at 37 degrees C for up to 1 h in the presence of either vasopressin (5 X 10(-9) mol/l) or angiotensin II (2.5 X 10(-7) mol/l). Aliquots of postincubation media were injected intravenously into anesthetized bioassay rats to determine natriuretic activity. Control media, in which atria had been incubated without agonist, did not cause natriuresis. Significant increases in sodium excretion were seen after injection of media in which atria had been incubated in the presence of either agonist. Injection of medium with the same agonist concentration did not result in comparable natriuresis. Radioimmunoassay (RIA) indicated a high concentration of immunoactive ANF in the natriuretic media. However, radioreceptor assay (RRA) of the same media gave apparent ANF concentrations that were lower by about three orders of magnitude. Because the antibody used in the RIA cross reacts with ANF prohormone, whereas the RRA is sensitive only to the active form, we concluded that agonist-induced, stretch-independent release of ANF is in the form of prohormone, which can be converted to the active hormone in the circulation of the bioassay animal. The conclusion of prohormone release was confirmed by liquid chromatography. The data thus suggest that receptor-mediated as well as stretch-induced ANF secretion may be important in regulating the activity of the ANF system.

scholarly journals The Chalcone Lonchocarpin Inhibits Wnt/β-Catenin Signaling and Suppresses Colorectal Cancer Proliferation

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1968 ◽  
Author(s):  
Danilo Predes ◽  
Luiz F. S. Oliveira ◽  
Laís S. S. Ferreira ◽  
Lorena A. Maia ◽  
João M. A. Delou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Active Form ◽  
Colorectal Cancer Cell ◽  
Intestinal Cell ◽  
Transcriptional Level ◽  
Mice Model

The deregulation of the Wnt/β-catenin signaling pathway is a central event in colorectal cancer progression, thus a promising target for drug development. Many natural compounds, such as flavonoids, have been described as Wnt/β-catenin inhibitors and consequently modulate important biological processes like inflammation, redox balance, cancer promotion and progress, as well as cancer cell death. In this context, we identified the chalcone lonchocarpin isolated from Lonchocarpus sericeus as a Wnt/β-catenin pathway inhibitor, both in vitro and in vivo. Lonchocarpin impairs β-catenin nuclear localization and also inhibits the constitutively active form of TCF4, dnTCF4-VP16. Xenopus laevis embryology assays suggest that lonchocarpin acts at the transcriptional level. Additionally, we described lonchocarpin inhibitory effects on cell migration and cell proliferation on HCT116, SW480, and DLD-1 colorectal cancer cell lines, without any detectable effects on the non-tumoral intestinal cell line IEC-6. Moreover, lonchocarpin reduces tumor proliferation on the colorectal cancer AOM/DSS mice model. Taken together, our results support lonchocarpin as a novel Wnt/β-catenin inhibitor compound that impairs colorectal cancer cell growth in vitro and in vivo.

Sign in / Sign up

Export Citation Format

Share Document